|
 |
| home > epc > winter 2001 > smos - creating a new outsourcing strategy for japanese pharmaceutical companies |
|
|
 PUBLICATIONS |
European Pharmaceutical Contractor
|
Japanese pharmaceutical companies wishing to conduct clinical research in Europe typically use contract research organisations (CROs), particularly those that offer 'full service' capabilities. Historically, this has been due to the fundamental fact that there is no alternative. Although some representative companies have sizeable clinical and regulatory departments, the majority of Japanese operations based in the UK or other European locations have a very small number of staff.
As a result, most global or multinational CROs have expended considerable effort in pursuing the attractive prospect of full service Japanese contracts, often in the hope that these will grow from single studies to full development programmes. In the very recent past, this has led to vigorous and expensive investment in operations and offices directly in Japan. This has been partly with a view to expanding their scope of work directly in the East, but also to improve the flow of projects and communications to their Western bases. Similarly, Japanese companies - wherever they are located - spend a considerable amount of time and resources debating and assessing the various strengths of the major CROs in performing certain studies.
|
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
Small Scale Biomanufacturing – clinical trials, cell & gene therapies
18 September 2008, Clifton Pavilion, Bristol Zoo Gardens, Bristol
This one day conference, sponsored by bioProcessUK and organised by BioApproaches South West, will cover key, important topics relating to small scale GMP biomanufacturing.
More info >> |
|
 |
News and Press Releases |
 |
Azopharma Product Development Group, Inc
HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today the addition of innovative state-of-the-art equipment at its formulation and manufacturing division, ApiCross Drug Delivery Technologies in Hollywood, Florida. The most recent acquisition is the MG Futura Capsule Filler which delivers the latest in capsule filling technology. The company has also added a Bausch & Strobel Aseptic Filling Isolator, equipment that is ground-breaking in the powder filling process. These additions support our previously implemented XcelodoseTM powder micro-dosing system. With these technologies, Azopharma is able to provide its clients with all forms of the capsule filling process. The new equipment is part of Azopharma’s recent manufacturing expansion which includes 17 new manufacturing suites for GMP, cytotoxic and aseptic products...
More info >> |
|
 |
